CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.

Biotechnology

CureVac

Alexander Zehnder

Axel Sven Malkomes

Christina Raikou

Oliver Grupp

Michael Noll

Thaminda Ramanayake

Nina Schmauk

Holger Nolte

Frank Keul

Myriam Mendila

Ulrike Gnad-Vogt

Malte Greune

Quality Management Team

Clinical Development Team

Leadership Team

Biophysical Chemistry and Analytics Team

Teams at CureVac

Quality Management Team

Clinical Development Team

Leadership Team

Biophysical Chemistry and Analytics Team